Insulin Market Analysis By Product (Fast Acting, Short Acting, Intermediate Acting, Pre-Mix and Long Acting), By Segments (Insulin Analogs And Human Recombinant Insulin), By Application (Type I and Type II Diabetes) And Segment Forecasts To 2020
The global market for insulin is expected to reach USD 47.54 billion by 2020. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as India and China are expected to be two of the most significant growth drivers of this market. Moreover, increasing incidence rates of lifestyle induced diseases such as obesity and growing global geriatric population base are expected to serve the global insulin market as drivers.
The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares.
Further key findings from the study suggest:
Insulin analogs were the most dominant source in 2013 and accounted for over 70% of the revenue. These products are rapidly substituting the human recombinant insulin products by exhibiting higher efficacy.
North America was the largest regional market in 2013, accounting for over 40% of global revenue. The presence of sophisticated healthcare infrastructure, high type I diabetes prevalence and patient disposable incomes in this region are some of the factors expected to drive market growth. Emerging markets including Asia Pacific accounted for 26.5% of global revenue in 2013.
Asia Pacific insulin market is expected to grow at the highest CAGR of over 15% from 2014 to 2020 on account of the presence of high unmet medical needs pertaining to diabetes and increasing healthcare expenditures in emerging markets such as India and China
Key industry participants include Sanofi, Novo Nordisk, Eli Lilly, Novartis, Biocon, Oramed Pharmaceuticals, Bristol-Myers Squibb, Takeda Pharmaceuticals, Dongbao Enterprise Group Co., Ltd. and others.
For the purpose of this study, Grand View Research has segmented the global insulin market on the basis of product, segment (on the basis of source), application and region:
The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares.
Further key findings from the study suggest:
Insulin analogs were the most dominant source in 2013 and accounted for over 70% of the revenue. These products are rapidly substituting the human recombinant insulin products by exhibiting higher efficacy.
North America was the largest regional market in 2013, accounting for over 40% of global revenue. The presence of sophisticated healthcare infrastructure, high type I diabetes prevalence and patient disposable incomes in this region are some of the factors expected to drive market growth. Emerging markets including Asia Pacific accounted for 26.5% of global revenue in 2013.
Asia Pacific insulin market is expected to grow at the highest CAGR of over 15% from 2014 to 2020 on account of the presence of high unmet medical needs pertaining to diabetes and increasing healthcare expenditures in emerging markets such as India and China
Key industry participants include Sanofi, Novo Nordisk, Eli Lilly, Novartis, Biocon, Oramed Pharmaceuticals, Bristol-Myers Squibb, Takeda Pharmaceuticals, Dongbao Enterprise Group Co., Ltd. and others.
For the purpose of this study, Grand View Research has segmented the global insulin market on the basis of product, segment (on the basis of source), application and region:
- Insulin Product Outlook
- Fast Acting Insulin
- Short Acting Insulin
- Intermediate Acting Insulin
- Long Acting Insulin
- Pre-Mixed Insulin
- Insulin Segment (on the basis of source) Outlook
- Insulin Analogs
- Human Recombinant Insulin
- Insulin Application Outlook
- Insulin for Type I Diabetes
- Insulin for Type II Diabetes
- Insulin Regional Outlook
- North America
- Europe
- Asia Pacific
- RoW
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Insulin – Industry Summary and Critical Success Factors (CSFs)
CHAPTER 2. INSULIN INDUSTRY OUTLOOK
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Insulin Market Dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Insulin - Company Market Share Analysis
2.7. Insulin Market PESTEL Analysis, 2012
2.8. Insulin – Pipeline Overview
CHAPTER 3. INSULIN PRODUCT OUTLOOK
3.1. Rapid Acting Insulin
3.1.1.Rapid Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.2. Short Acting Insulin
3.2.1.Short Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Intermediate Acting Insulin
3.3.1.Intermediate Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Long Acting Insulin
3.4.1.Long Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Pre-Mixed Acting Insulin
3.5.1.Pre-Mixed Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 4. INSULIN SEGMENT (ON THE BASIS OF SOURCE) OUTLOOK
4.1. Insulin Analogs
4.1.1.Insulin Analogs Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.2. Human Recombinant Insulin
4.2.1.Human Recombinant Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 5. INSULIN APPLICATION OUTLOOK
5.1. Type I Diabetes
5.1.1.Insulin for Type I Diabetes Market Estimates and Forecasts, 2012 – 2020 (USD Million)
5.2. Type II Diabetes
5.2.1.Insulin for Type II Diabetes Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 6. INSULIN REGIONAL OUTLOOK
6.1. North America
6.1.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.1.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.1.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.2. Europe
6.2.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.2.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.2.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.3. Asia Pacific
6.3.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.3.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.3.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.4. RoW
6.4.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.4.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.4.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1 Sanofi Aventis
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Takeda Pharmaceuticals
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Eli Lilly
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Oramed Pharmaceuticals Inc.
7.4.1 Company Overview
7.4.2 Product Benchmarking
7.4.3 Strategic Initiatives
7.5 Nanjing Xinbai Pharmaceutical Co., Ltd.
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Strategic Initiatives
7.6 Gan & Lee Pharmaceuticals Co. Ltd.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Boehringer Ingelheim
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Merck & Co. Inc.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 Dongbao Enterprises Group Co. Ltd.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Halozyme Therapeutics
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
7.11 Novo Nordisk
7.11.1 Company Overview
7.11.2 Financial Performance (Net Sales for Insulin)
7.11.3 Product Benchmarking
7.11.4 Strategic Initiatives
7.12 Bristol-Myers Squibb
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Strategic Initiatives
7.13 Biocon
7.13.1 Company Overview
7.13.2 Financial Performance
7.13.3 Product Benchmarking
7.13.4 Strategic Initiatives
7.14 Wanbang Biopharmaceuticals
7.14.1 Company Overview
7.14.2 Financial Performance
7.14.3 Product Benchmarking
CHAPTER 8. METHODOLOGY AND SCOPE
8.1. Research Methodology
8.2. Research Scope & Assumption
8.3. List of Data Sources
1.1. Insulin – Industry Summary and Critical Success Factors (CSFs)
CHAPTER 2. INSULIN INDUSTRY OUTLOOK
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Insulin Market Dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Insulin - Company Market Share Analysis
2.7. Insulin Market PESTEL Analysis, 2012
2.8. Insulin – Pipeline Overview
CHAPTER 3. INSULIN PRODUCT OUTLOOK
3.1. Rapid Acting Insulin
3.1.1.Rapid Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.2. Short Acting Insulin
3.2.1.Short Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Intermediate Acting Insulin
3.3.1.Intermediate Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Long Acting Insulin
3.4.1.Long Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Pre-Mixed Acting Insulin
3.5.1.Pre-Mixed Acting Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 4. INSULIN SEGMENT (ON THE BASIS OF SOURCE) OUTLOOK
4.1. Insulin Analogs
4.1.1.Insulin Analogs Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.2. Human Recombinant Insulin
4.2.1.Human Recombinant Insulin Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 5. INSULIN APPLICATION OUTLOOK
5.1. Type I Diabetes
5.1.1.Insulin for Type I Diabetes Market Estimates and Forecasts, 2012 – 2020 (USD Million)
5.2. Type II Diabetes
5.2.1.Insulin for Type II Diabetes Market Estimates and Forecasts, 2012 – 2020 (USD Million)
CHAPTER 6. INSULIN REGIONAL OUTLOOK
6.1. North America
6.1.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.1.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.1.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.2. Europe
6.2.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.2.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.2.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.3. Asia Pacific
6.3.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.3.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.3.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
6.4. RoW
6.4.1.Insulin Market Estimates and Forecasts, by Products, 2012 – 2020 (USD Million)
6.4.2.Insulin Market Estimates and Forecasts, by Segments, 2012 – 2020 (USD Million)
6.4.3.Insulin Market Estimates and Forecasts, by Applications, 2012 – 2020 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1 Sanofi Aventis
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Takeda Pharmaceuticals
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Eli Lilly
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Oramed Pharmaceuticals Inc.
7.4.1 Company Overview
7.4.2 Product Benchmarking
7.4.3 Strategic Initiatives
7.5 Nanjing Xinbai Pharmaceutical Co., Ltd.
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Strategic Initiatives
7.6 Gan & Lee Pharmaceuticals Co. Ltd.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Boehringer Ingelheim
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Merck & Co. Inc.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 Dongbao Enterprises Group Co. Ltd.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Halozyme Therapeutics
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
7.11 Novo Nordisk
7.11.1 Company Overview
7.11.2 Financial Performance (Net Sales for Insulin)
7.11.3 Product Benchmarking
7.11.4 Strategic Initiatives
7.12 Bristol-Myers Squibb
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Strategic Initiatives
7.13 Biocon
7.13.1 Company Overview
7.13.2 Financial Performance
7.13.3 Product Benchmarking
7.13.4 Strategic Initiatives
7.14 Wanbang Biopharmaceuticals
7.14.1 Company Overview
7.14.2 Financial Performance
7.14.3 Product Benchmarking
CHAPTER 8. METHODOLOGY AND SCOPE
8.1. Research Methodology
8.2. Research Scope & Assumption
8.3. List of Data Sources
LIST OF TABLES
Insulin – Industry summary & Critical Success Factors (CSFs)
Global Insulin revenue, 2012 - 2020
Global insulin market revenue by region, 2012 - 2020 (USD million)
Global Insulin market revenue by products, 2012 - 2020 (USD million)
Global fast acting insulin market, 2012 to 2020 (USD million)
Global pre-mixed acting insulin market, 2012 to 2020 (USD million)
Global short acting insulin market, 2012 to 2020 (USD million)
Global intermediate acting insulin market, 2012 to 2020 (USD million)
Global long acting insulin market, 2012 to 2020 (USD million)
Global insulin market revenue by segments, 2012 - 2020 (USD million)
Global insulin analogs market, 2012 to 2020 (USD million)
Global human recombinant insulin market, 2012 to 2020 (USD million)
Global insulin market revenue by applications, 2012 - 2020 (USD million)
Global insulin for type I diabetes market, 2012 to 2020 (USD million)
Global insulin for type II diabetes market, 2012 to 2020 (USD million)
Global insulin market, by region, 2012 to 2020 (USD million)
North America insulin demand, by products, 2012 – 2020 (USD million)
North America insulin demand, by segments, 2012 – 2020 (USD million)
North America insulin demand, by applications, 2012 - 2020 (USD million)
Europe insulin demand, by products, 2012 – 2020 (USD million)
Europe insulin demand, by segments, 2012 – 2020 (USD million)
Europe insulin demand, by applications, 2012 - 2020 (USD million)
Asia Pacific insulin demand, by products, 2012 – 2020 (USD million)
Asia Pacific insulin demand, by segments, 2012 – 2020 (USD million)
Asia Pacific insulin demand, by applications, 2012 - 2020 (USD million)
RoW insulin demand, by products, 2012 – 2020 (USD million)
RoW insulin demand, by segments, 2012 – 2020 (USD million)
RoW insulin demand, by applications, 2012 - 2020 (USD million)
Global Insulin Market - Competitive Landscape
Insulin – Industry summary & Critical Success Factors (CSFs)
Global Insulin revenue, 2012 - 2020
Global insulin market revenue by region, 2012 - 2020 (USD million)
Global Insulin market revenue by products, 2012 - 2020 (USD million)
Global fast acting insulin market, 2012 to 2020 (USD million)
Global pre-mixed acting insulin market, 2012 to 2020 (USD million)
Global short acting insulin market, 2012 to 2020 (USD million)
Global intermediate acting insulin market, 2012 to 2020 (USD million)
Global long acting insulin market, 2012 to 2020 (USD million)
Global insulin market revenue by segments, 2012 - 2020 (USD million)
Global insulin analogs market, 2012 to 2020 (USD million)
Global human recombinant insulin market, 2012 to 2020 (USD million)
Global insulin market revenue by applications, 2012 - 2020 (USD million)
Global insulin for type I diabetes market, 2012 to 2020 (USD million)
Global insulin for type II diabetes market, 2012 to 2020 (USD million)
Global insulin market, by region, 2012 to 2020 (USD million)
North America insulin demand, by products, 2012 – 2020 (USD million)
North America insulin demand, by segments, 2012 – 2020 (USD million)
North America insulin demand, by applications, 2012 - 2020 (USD million)
Europe insulin demand, by products, 2012 – 2020 (USD million)
Europe insulin demand, by segments, 2012 – 2020 (USD million)
Europe insulin demand, by applications, 2012 - 2020 (USD million)
Asia Pacific insulin demand, by products, 2012 – 2020 (USD million)
Asia Pacific insulin demand, by segments, 2012 – 2020 (USD million)
Asia Pacific insulin demand, by applications, 2012 - 2020 (USD million)
RoW insulin demand, by products, 2012 – 2020 (USD million)
RoW insulin demand, by segments, 2012 – 2020 (USD million)
RoW insulin demand, by applications, 2012 - 2020 (USD million)
Global Insulin Market - Competitive Landscape
LIST OF FIGURES
Insulin Market Segmentation
Global Insulin Market Revenue, 2012 - 2020
Insulin Market Dynamics
Insulin Company Market Share Analysis, 2012
Key Opportunities Prioritized
Industry Analysis - Porter's
Insulin PESTEL Analysis, 2012
Global Insulin market, by products, 2012 – 2020 (USD million)
Global fast acting insulin market, by region, 2012 – 2020 (USD million)
Global short acting insulin market, by region, (USD million), 2012 - 2020
Global intermediate insulin acting market, by region, (USD million), 2012 - 2020
Global long acting insulin market, by region, 2012 - 2020 (USD million)
Global pre-mix acting insulin market, by region, 2012 - 2020 (USD million)
Global Insulin market, by segments, 2012 – 2020 (USD million)
Global insulin analogs market, by region, 2012 – 2020 (USD million)
Global human recombinant insulin market, by region, 2012 – 2020 (USD million)
Global Insulin market, by applications, 2012 – 2020 (USD million)
Global insulin for type I diabetes market, by region, 2012 – 2020 (USD million)
Global insulin for type II diabetes market, by region, 2012 – 2020 (USD million)
Global insulin market, by region, 2012 - 2020 (USD million)
Insulin market - company market share analysis, 2013 (%)
Insulin Market Segmentation
Global Insulin Market Revenue, 2012 - 2020
Insulin Market Dynamics
Insulin Company Market Share Analysis, 2012
Key Opportunities Prioritized
Industry Analysis - Porter's
Insulin PESTEL Analysis, 2012
Global Insulin market, by products, 2012 – 2020 (USD million)
Global fast acting insulin market, by region, 2012 – 2020 (USD million)
Global short acting insulin market, by region, (USD million), 2012 - 2020
Global intermediate insulin acting market, by region, (USD million), 2012 - 2020
Global long acting insulin market, by region, 2012 - 2020 (USD million)
Global pre-mix acting insulin market, by region, 2012 - 2020 (USD million)
Global Insulin market, by segments, 2012 – 2020 (USD million)
Global insulin analogs market, by region, 2012 – 2020 (USD million)
Global human recombinant insulin market, by region, 2012 – 2020 (USD million)
Global Insulin market, by applications, 2012 – 2020 (USD million)
Global insulin for type I diabetes market, by region, 2012 – 2020 (USD million)
Global insulin for type II diabetes market, by region, 2012 – 2020 (USD million)
Global insulin market, by region, 2012 - 2020 (USD million)
Insulin market - company market share analysis, 2013 (%)
